Skip to main content

Table 1 Summary for the clinical features of the pSS patients and healthy controls enrolled in this study

From: The potential roles of type I interferon activated neutrophils and neutrophil extracellular traps (NETs) in the pathogenesis of primary Sjögren’s syndrome

Clinical features

pSS patients (n=50)

Healthy controls (n=44)

Sex (female)

49

43

Age (Mean±S.D.)

48.19±15.13

43.85±11.35

Disease duration (median, IQR)

24 (6~48)

N/A

Fever (n%)

2 (4.00%)

0

Joint pain (n%)

17 (34.00%)

0

Extra-glandular organ involvement

19 (38.00%)

0

ESSDAI (Mean±S.D.)

4.2±3.1

N/A

Serological examinations (Median, IQR)

 IgG (g/L)

18.74 (13.85~26)

N/A

 IgA (g/L)

2.85 (1.84~3.41)

N/A

 IgM (g/L)

1.16 (0.74~1.38)

N/A

 C3 (g/L)

1.05 (0.91~1.15)

N/A

 C4 (g/L)

0.17 (0.15~0.21)

N/A

 RF (IU/ml)

106.5 (18.75~236.75)

N/A

 ESR (mm/h)

17 (11~41.75)

N/A

 CRP (mg/L)

0.79 (0.31~1.75)

N/A

 Anti-SSA antibody (n%)

49 (98.00%)

0

 Anti-SSB antibody (n%)

23 (46.00%)

0

 Anti-Ro52 antibody (n%)

39 (78.00%)

0

  1. Age for pSS patients represented for age at onset, and for healthy controls represented for the age at which the blood samples were collected. ESSDAI represented for EULAR primary Sjögren’s syndrome disease activity index and was used to evaluate the disease activity of pSS patients
  2. S.D. standard deviation, IQR interquartile range, N/A not applicable, ESR erythrocyte sedimentation rate, CRP C-reaction protein, IgG, IgA, IgM immunoglobulin G, immunoglobulin A, immunoglobulin M, C3, C4 complement 3, complement 4, RF rheumatic factor, ANAs antinuclear antibodies